We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-12.3%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$784M
AUM Growth
-$237M
Cap. Flow
-$75.7M
Cap. Flow %
-9.66%
Top 10 Hldgs %
46.1%
Holding
163
New
33
Increased
30
Reduced
43
Closed
36

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$37.3M
2
INCY icon
Incyte
INCY
+$11.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.68M
4
SHPG
Shire pic
SHPG
+$8.32M
5
BIIB icon
Biogen
BIIB
+$8.01M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$22.8M
2
GILD icon
Gilead Sciences
GILD
+$22.2M
3
PFE icon
Pfizer
PFE
+$10.1M
4
CXRX
Concordia International Corp. Common Stock
CXRX
+$9.03M
5
VRNT
Verint Systems
VRNT
+$8.47M

Sector Composition

Rank Sector Weight
1 Healthcare 55.74%
2 Industrials 4.06%
3 Utilities 2.54%
4 Technology 1.27%
5 Consumer Discretionary 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
126
PTC Therapeutics
PTCT
$5.68B
$107K 0.01%
4,000
-62,500
-94% -$2.67M
AIMT
127
DELISTED
Aimmune Therapeutics
AIMT
$5K ﹤0.01%
+200
New +$4.68K
AAPL icon
128
Apple
AAPL
$4.54T
– –
-92,892
Closed -$2.91M
BMRN icon
129
CALL
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-1,000
Closed -$13.7M
EWG icon
130
iShares MSCI Germany ETF
EWG
$1.59B
– –
-192,630
Closed -$5.37M
FEZ icon
131
State Street SPDR EURO STOXX 50 ETF
FEZ
$4.42B
– –
-104,920
Closed -$3.93M
GALT icon
132
Galectin Therapeutics
GALT
$196M
– –
-205,000
Closed -$560K
KRE icon
133
State Street SPDR S&P Regional Banking ETF
KRE
$4.5B
– –
-80,080
Closed -$3.54M
MRK icon
134
Merck
MRK
$322B
– –
-419,200
Closed -$22.8M
OCUL icon
135
Ocular Therapeutix
OCUL
$1.79B
– –
-160,000
Closed -$3.37M
PRGO icon
136
Perrigo
PRGO
$1.4B
– –
-273
Closed -$50.1K
SNA icon
137
Snap-on
SNA
$21.2B
– –
-15,340
Closed -$2.44M
SPNS
138
DELISTED
Sapiens International
SPNS
– –
-56,420
Closed -$586K
TEVA icon
139
CALL
Teva Pharmaceuticals
TEVA
$40.8B
– –
-6,500
Closed -$38.4M
VFC icon
140
VF Corp
VFC
$5.63B
– –
-18,691
Closed -$1.23M
VRNT
141
DELISTED
Verint Systems
VRNT
– –
-273,709
Closed -$8.47M
VIRX
142
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-5,881
Closed -$3.72M
TRVN
143
DELISTED
Trevena, Inc.
TRVN
– –
-656
Closed -$2.57M
CYTO
144
DELISTED
Altamira Therapeutics Ltd
CYTO
– –
-1
Closed -$316K
APTO
145
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-491
Closed -$1.42M
OTIC
146
DELISTED
Otonomy, Inc.
OTIC
– –
-113,000
Closed -$2.6M
AGTC
147
DELISTED
Applied Genetic Technologies Corporation
AGTC
– –
-200,124
Closed -$3.07M
ZSAN
148
DELISTED
Zosano Pharma Corporation
ZSAN
– –
-89
Closed -$452K
IMMU
149
DELISTED
Immunomedics Inc
IMMU
– –
-245,000
Closed -$995K
BCOM
150
DELISTED
B Communications Ltd
BCOM
– –
-5,977,000
Closed -$6.45M
3 4 5
6
7

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sphera Funds Management held 163 positions worth $784M, down 23% from $1.02B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sphera Funds Management withdrew a net $75.7M in Q3 2015, closing 36 positions and reducing 43 holdings. Its most notable exit was Merck, an estimated $22.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 51% a quarter earlier, followed by Industrials and Utilities.

Against the trend, Sphera Funds Management opened a new position in Incyte worth $11M.

  • Sphera Funds Management's largest Q3 2015 buy was Incyte: 100,000 shares worth $11M.
  • Sphera Funds Management added most to Teva Pharmaceuticals in Q3 2015, an estimated $37.3M increase.
  • Sphera Funds Management's biggest Q3 2015 reduction was Gilead Sciences, cutting an estimated $22.2M.
  • Sphera Funds Management fully exited Merck in Q3 2015, selling an estimated $22.8M.
  • Sphera Funds Management's ten largest holdings make up 46% of its $784M portfolio in Q3 2015.
  • Sphera Funds Management opened 33 new positions and closed 36 in Q3 2015.
  • Sphera Funds Management's portfolio value fell 23% quarter-over-quarter to $784M.

Based on Sphera Funds Management's 13F filing for Q3 2015, filed 16 Nov 2015.